XML 71 R60.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaboration and Licensing Revenue - Additional Information (Details) - USD ($) | 1 Months Ended | 5 Months Ended
--- | --- | ---
Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | May 31, 2016
Exotech Bio, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |
Exotech Bio, Inc. | Maximum |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payments to be received upon successful achievement, per product |  |  | $ 52,500,000 |
Exotech Bio, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value |  |  | $ 5,000,000 |
Relieve Genetics, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |
Relieve Genetics, Inc. | Maximum |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payments to be received upon successful achievement, per product |  |  | $ 52,500,000 |
Relieve Genetics, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value |  |  | $ 4,333,000 |
Intrexon T1D Partners |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  | 90 days |
Intrexon T1D Partners | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value |  |  | $ 10,000,000 |
AD Skincare, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  | 90 days |  |
AD Skincare, Inc. | Maximum |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payments to be received upon successful achievement, per product |  | $ 2,000,000 |  |
Milestone payments to be received upon successful achievement, one-time |  | 17,000,000 |  |
AD Skincare, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value |  | $ 4,333,000 |  |
ZIOPHARM Oncology, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Royalty rate as a percentage of net profit |  | 20.00% |  | 50.00%
ZIOPHARM Oncology, Inc. | Other Contractual Payments | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value |  | $ 120,000,000 |  |
Collaborative arrangement consideration received, number of preferred shares (in shares) |  | 100,000 |  |
Genten Therapeutics, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement | 90 days |  |  |
Genten Therapeutics, Inc. | Maximum |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payments to be received upon successful achievement, per product | $ 82,000,000 |  |  |
Genten Therapeutics, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value | 3,000,000 |  |  |
Collaborative arrangement consideration received in the form of cash | $ 1,500,000 |  |  |
CRS Bio, Inc. |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Required notice period for voluntary termination of collaborative agreement | 90 days |  |  |
CRS Bio, Inc. | Maximum |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Milestone payments to be received upon successful achievement, per product | $ 75,000,000 |  |  |
CRS Bio, Inc. | Upfront | Upfront and Milestone Payments |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |
Collaborative arrangement consideration received, value | $ 2,100,000 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notice period required for voluntary termination of collaboration. + References No definition available. + Details
Name: | xon_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash received by the entity as consideration for collaboration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedCash
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of preferred stock of a collaborator received by the entity as consideration. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedPreferredShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of consideration received by the entity for collaboration + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of net profit, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled. + References No definition available. + Details
Name: | xon_CollaborativeArrangementRoyaltyRateAsPercentageOfNetProfit
Namespace Prefix: | xon_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement one-time + References No definition available. + Details
Name: | xon_MilestonePaymentsRequiredUponSuccessfulAchievementOneTime
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement per product + References No definition available. + Details
Name: | xon_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ExotechBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_UpfrontMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_RelieveGeneticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ADSkincareInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_OtherContractualPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_GentenTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_CRSBioInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |